A market forecast published by IndexBox projects the global non-insulin peptide drugs market growing at a 9.4% compound annual rate from 2026 to 2035, with manufacturing capacity, not demand, named as the limiting factor.

Non-insulin peptide drugs is the industry's catch-all for everything from GLP-1 receptor agonists such as those used in obesity and type 2 diabetes care, through peptide-drug conjugates in oncology, to somatostatin analogs for rare conditions like acromegaly. IndexBox models the sector as an index rather than absolute volumes, and puts it at roughly 245 by 2035 against a 2025 baseline of 100, a convention the firm says it uses when full volumes are not publicly disclosed.

Where the growth comes from

Metabolic disorders are described as the largest and fastest-growing end-use segment, dominated by GLP-1 receptor agonists. IndexBox expects the addressable patient population to keep expanding as clinical guidelines endorse broader use and oral formulations improve accessibility.

Oncology is the high-value segment: peptide-drug conjugates, radiolabeled peptides and peptide vaccines, currently used in neuroendocrine tumors, prostate cancer and certain lymphomas. Rare disease and cardiovascular applications sit behind it, the latter described as emerging rather than established, with natriuretic peptides used mainly as biomarkers today.

The synthesis bottleneck

The more interesting half of this report is the supply side, and it is the part the GLP-1 coverage usually skips. IndexBox says the market is not constrained by raw materials but by the technical and quality-control expertise needed for GMP-grade synthesis at scale.

That creates high barriers to entry and pushes bargaining power toward contract manufacturers. Buyers, the report says, prioritize regulatory track record and technical capability over price, which is an unusual procurement pattern and a good signal of how tight qualified capacity actually is.

Who makes it and where

North America leads on adoption and premium pricing, Europe is characterized as mature with steady growth, and Asia-Pacific is the fastest-growing region, with China and India becoming hubs for peptide API production. Named participants across segments include Novo Nordisk, Eli Lilly, Novartis, Ipsen, Bachem and Ferring.

Bottom line

This is a commercial forecast, not clinical evidence, and its central number is an index rather than a dollar figure. What it adds to the picture is a reminder that the constraint on peptide medicine through 2035 may be factory qualification rather than pipeline science.